As of January 1, 2018, Mr. Marc van Barneveld has left U-Needle’s Board, to fully focus on his product development company Factim BV.
Mr. Van Barneveld successfully led the company in the development of U-Needles first microneedle device “Bella-mu“, for which CE approval is expected in February 2018. Currently U-Needle shifts her focus from microneedle R&D towards clinical applications of Bella-mu and related products in the field of aesthetics, vaccination and diabetes.
In 2011 Mr. van Barneveld started the Bella-mu development for the Aesthetics field. After initial research years, to grow the technology with a small team of highly skilled developers, he successfully set-up the full scope ISO13485 quality system, leading to certification in 2016. Recently, U-Needle filed for CE approval of Bella-mu, completing the challenge Marc initially faced in 2011.
“We thank Marc for all he has done for the company and wish him all the best with Factim” said Mr. Wissink, U-Needle’s Founder and Managing Director, on behalf of all shareholders. “Missing his tremendous skills in product conceptualization and development, combined with his deep experience in engineering and tooling, will be a great loss to U-Needle.” From within Factim, Mr. Van Barneveld will remain involved in U-Needle to assist in product development and train younger colleagues to extend the U-Needle competences and use the generated Bella-mu knowledge for future generation microneedle devices.
Bonne chance Marc!
U-Needle develops proprietary microneedle technology applied in various user-friendly intradermal injection devices for aesthetics, vaccination and diabetes therapies.
The advanced microneedle technology facilitates fast therapy onset and reduced dose in pharmaceutical injectables.